Elliott Sigal, M.D., Ph.D.

-Executive Vice President, Chief Scientific Officer and President, Research and Development Bristol-Myers Squibb
 
Education:
B.S., M.S. (1973) – Purdue University, Indiana (Industrial Engineering)
Ph.D. (1977) – Purdue University, Indiana (Engineering)
M.D. (1981 )- University of Chicago, Illinois

Bio:
Elliot Sigal was appointed Executive Vice President of Bristol-Myers Squibb in 2006 and has been a member of the company’s Senior Management Team since 2001.  He has been a leading contributor to the strategy for the company’s transformation to a next-generation biopharmaceutical company fully dedicated to innovative therapies for unmet medical needs.  He has been instrumental in increasing R&D productivity, acquiring external innovation, and helping to develop the company’s strategy in biologics.  Doctor Sigal also serves as a member of the Board of Directors for the Mead Johnson Nutrition Company.

Under his leadership, ten new medicines have come to market including Abilify (Schizophrenia, Bipolar Disorder), Reyataz (HIV/AIDS), Erbitux (Colon Cancer), Baraclude (Hepatitis B), Orencia (Rheumatoid Arthritis), Sprycel (Leukemia), Atripla (HIV/AIDS), Ixempra (Breast Cancer) and Onglyza (Diabetes). Dr. Sigal has been in leadership positions at Bristol-Myers Squibb in both Research and in Development.

He started as Vice President of the newly created department of Applied Genomics in 1997.  In 1999, he became Senior Vice President for Early Discovery and Applied Technology.  He was named Head of Drug Discovery & Exploratory Development in 2001, Head of Development in 2002 and Head of R&D in 2004.

Doctor Sigal has more than 25 years of combined experience in medicine, research and management.  In 1992 he joined the pharmaceutical company Syntex and held positions of increasing responsibility in drug discovery.  In 1995 Dr. Sigal joined the genomics firm Mercator Genetics as Vice President of Research and Development and later served as CEO.  While there he provided the research leadership that resulted in the discovery of the gene for hemochromatosis, a common disorder that leads to iron overload, diabetes and liver disease.